Atea Pharmaceuticals Inc.
(NASDAQ:AVIR) announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.
The C-BEYOND study enrolled 905 patients and met its primary endpoint.
The data demonstrated that a once-daily fixed-dose combination of bemnifosbuvir and ruzasvir achieved statistical non-inferiority compared to Gilead Sciences Inc.'s (NASDAQ:GILD) Epclusa (sofosbuvir and velpatasvir) in a modified intent-to-treat population.
Phase 3 Trial Efficacy Outcomes In the overall modified intent-to-treat analysis encompassing cirrhotic and non-cirrhotic patients, the experimental dual-drug combination achieved a 93.9% sustained virologic response rate at 24 weeks, compared to 94.8% for the control group.
